Provided by Tiger Fintech (Singapore) Pte. Ltd.

Protalix BioTherapeutics

3.06
+0.10143.43%
Volume:848.72K
Turnover:2.58M
Market Cap:238.89M
PE:83.52
High:3.10
Open:2.96
Low:2.87
Close:2.96
Loading ...

Barclays Sticks to Their Hold Rating for PLUXEE N.V. (PLX)

TIPRANKS
·
30 Jan

Kepler Capital Sticks to Its Buy Rating for PLUXEE N.V. (PLX)

TIPRANKS
·
10 Jan

PLUXEE N.V. (PLX) Gets a Hold from UBS

TIPRANKS
·
09 Jan

Protalix BioTherapeutics Issues 2025 Letter to Stockholders

PR Newswire
·
23 Dec 2024

Barclays Sticks to Their Hold Rating for PLUXEE N.V. (PLX)

TIPRANKS
·
13 Dec 2024

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa

PR Newswire
·
09 Dec 2024

Pluri assesses readiness to mass produce PLX-R18

TIPRANKS
·
25 Nov 2024

PLX: Self-Sustaining Rise to Lead in Renal Rare Disease

Zacks Small Cap Research
·
15 Nov 2024

Protalix BioTherapeutics Inc (PLX) Q3 2024 Earnings Call Highlights: Revenue Surge and ...

GuruFocus.com
·
15 Nov 2024

Protalix BioTherapeutics Reports Strong Q3 2024 Results

TIPRANKS
·
15 Nov 2024

Protalix: Q3 Earnings Snapshot

Associated Press Finance
·
14 Nov 2024

Protalix BioTherapeutics Q3 2024 GAAP EPS $0.03 Misses $0.06 Estimate, Sales $17.96M Beat $16.26M Estimate

Benzinga
·
14 Nov 2024

Press Release: Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results

Dow Jones
·
14 Nov 2024

Kepler Capital Remains a Buy on PLUXEE N.V. (PLX)

TIPRANKS
·
10 Nov 2024

PLUXEE N.V. (PLX) Receives a Hold from Barclays

TIPRANKS
·
08 Nov 2024

Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024

PR Newswire
·
07 Nov 2024

PLUXEE N.V. (PLX) Receives a Buy from Kepler Capital

TIPRANKS
·
02 Nov 2024

Barclays Sticks to Its Hold Rating for PLUXEE N.V. (PLX)

TIPRANKS
·
01 Nov 2024